With earlier diagnosis, the prognosis of those with liver cancer is greatly improved. Our VeraMarker™ metabolite profiling test enables early, more accurate diagnosis.
The need for improved cancer diagnostics is compelling. Yet molecular diagnostics employing DNA, RNA, and proteins have not delivered as expected with actionable clinical tests.
Investor + Partner Ready
Matrix-Bio is seeking investors and strategic partners to validate our potentially clinically superior VeraMarker™ liver cancer diagnostics test.